Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

How Will the Pharma Industry Perform in 2024 & the Near Term?

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Getting the latest market analysis and data

Graham Lewis 
Vice President, Global Pharma Strategy 
IQVIA

What are the key growth indicators for the global bio/pharmaceutical market in 2024 and over the next several years, and how will the industry perform over this time?  That is the trillion-dollar question for the bio/pharma industry.

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing valuable market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharma market analysis, will provide the latest market data and trends.

COVID-19 vaccines and therapeutics had been a boon for the industry, but with lower growth for these products, how will the industry perform relative to pre-pandemic growth trends? Is the industry’s performance trending upward or not? The program will examine the growth prospects and factors influencing performance for: innovator and generic drugs; leading therapeutic sectors, both pipelines and commercial products; and developed and emerging markets.

Daniel Cohen 
Managing Director & Global Head of Pharma Outsourcing Investment Banking
Morgan Stanley

A CMDO/CMO financial outlook
The performance of the industry as a whole is a factor in determining the health of the market for pharmaceutical outsourcing, which is further influenced by other factors. The program will also feature a Wall Street view of the CDMO/CMO sector, with Daniel Cohen, Managing Director & Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley, providing a financial overview of the CDMO/CMO sector: performance & investor valuations. He will provide an analysis of key mergers & acquisitions and other trends impacting sector performance.

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 18, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for pre-program networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM. 

Information on the program, including how to register, may be found here.

Recent Feature Articles

Making the Innovation Cut: New Drug Approvals Thus Far in 2024

By
How is product innovation faring in the bio/pharma industry thus far in 2024? Through the end of October, FDA’s Center for Drug Evaluation and Research has approved 38 new drugs. Which companies  and products have made the cut, and which may be best poised for market success?

Mark Your Calendar: Mitigating Supplier Risk for Steady-State Operations

By
Continual monitoring and evaluation of risk once working with suppliers is critical. An upcoming DCAT webinar will provide a customer–supplier view of the key performance indicators. key risk indicators, challenges, and scenarios to take into consideration to mitigate risk.

Tracking Innovation in RNA Manufacturing

By
The success of mRNA-based COVID-19 vaccines has generated interest in RNA-based drug development, with over 200 RNA drugs estimated to be in development. The promise of RNA medicines in turn has engendered innovation in manufacturing these drugs, including from start-up companies.

What’s in Store for the Global Economy

By
With the rate of inflation continuing to moderate, some economists are projecting a soft landing is in place and that overall economic growth is expected to be steady, but some headwinds still remain. What can be expected for the remainder of this year and in the near term?